Terran Biosciences Receives FDA Clearance for NM-101, the Industry’s First Software for the analysis of Neuromelanin-sensitive MRI
Imaging Technology
DECEMBER 20, 2023
We believe this technology could become very important in the clinical workflow of patients with neurological and psychiatric disorders.” While neuromelanin was first described in the 19 th century, researchers have elucidated its possible role as a biomarker for neurological disorders such as Parkinson’s disease in the last two decades.
Let's personalize your content